drugset
drugset / Trial / NCT05443724

A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

NCT05443724 ↗

Phase 2 Completed 700 enrolled AbbVie
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.

Timeline

Start
2022-09-02
Primary completion
2025-06-25
Completion
2025-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule 30 mg Oral

Indications

schizophrenia